Clinical Trial Update: Universal Chimeric Antigen Receptor T-Cell （UCAR T-cell） Therapy Targeting CD19/ BCMA（QT-019C） in Patients With r/ r Neurological Autoimmune Diseases [EARLY_Phase 1]

View source ↗

Summary

This document reports an early-phase (Phase 1) clinical trial of QT-019C UCAR T-cell therapy targeting CD19 and BCMA in relapsed/refractory neurological autoimm…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis
• Myasthenia Gravis
• Neuromyelitis Optica Spectrum Disorder

Drugs mentioned

• QT-019C UCAR T-cell therapy (QT-019C UCAR T-cell therapy)

Snippet

Sponsor: Tianjin Huanhu Hospital | Conditions: Neuromyelitis Optica Spectrum Disorders, Multiple Sclerosis | EARLY_Phase 1 | Status: NOT_YET_RECRUITING